(s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof
AssigneeTranslational Drug Development, LLC
InventorsTong Wang, Stephen Gately
Life of this patent
Estimating the term…
Abstract
The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.
Claims25
1-20. (canceled)
A pharmaceutical composition in which the active ingredient consists essentially of:
- (S)—N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide, or a pharmaceutically acceptable salt or solvate thereof.
A pharmaceutical composition in which the active ingredient comprises:
- (S)—N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide, or a pharmaceutically acceptable salt or solvate thereof,
- wherein the composition demonstrates significantly increased Vz/F or apparent volume of distribution during terminal phase after oral administration compared to N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide or (R)—N-hydroxy-2-(2-(4-methoxy-phenyl)butanamido)thiazole-5-carboxamide indicating preferential and significant tumor uptake and retention.
A pharmaceutical composition in which the active ingredient comprises:
- N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide, or a pharmaceutically acceptable salt or solvate thereof,
- wherein the active ingredient comprises at least 80% (S)—N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide.
Dependencies are inferred from the claim text.